Site-Specific TLR7 Agonist Antibody-Drug Conjugates as Next Generation ADCs

Time: 1:00 pm
day: Day Two


  • Presenting on the site-specific TLR7a ADC developed by EuCODE platform with an expanded genetic code
  • Reviewing how protein medicinal chemistry enables fine-tuning of TLR7a ADC to balance potency and safety in preclinical studies
  • Demonstrating how Ambrx’s TLR7a ADCs elicit strong anti-tumor responses as single-agent as well as in combination therapies